Abbott completes separation of research-based pharmaceuticals business
Advertisement
Abbott announced it has completed the separation of its research-based pharmaceuticals business, which became AbbVie, a new independent biopharmaceutical company. AbbVie begins trading independently on the New York Stock Exchange under the symbol "ABBV."
"We wish our colleagues at AbbVie continued success as they become part of a new, independent company that is already making a significant difference, focusing on highly specialized, market-leading therapies for some of the world's most difficult-to-treat diseases," said Miles D. White, chairman and chief executive officer, Abbott.